1. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate
- Author
-
Susumu Ohshiro, Norio Hobara, Matao Sakanashi, Nobuo Hokama, Narumi Hobara, and Hiromasa Kameya
- Subjects
Male ,Monocarboxylic Acid Transporters ,medicine.medical_treatment ,Sodium ,Pharmaceutical Science ,chemistry.chemical_element ,Pharmacology ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Pharmacokinetics ,Oral administration ,medicine ,Animals ,Drug Interactions ,Benzoic acid ,Valproic Acid ,Rizatriptan Benzoate ,Triazoles ,Drug interaction ,Tryptamines ,Rats ,Serotonin Receptor Agonists ,Anticonvulsant ,chemistry ,Anticonvulsants ,lipids (amino acids, peptides, and proteins) ,medicine.drug - Abstract
Drug interaction between rizatriptan benzoate, an anti-migraine agent, and sodium valproate (VPA-Na), an anticonvulsant, was studied in rats. When rizatriptan benzoate was administered orally immediately after VPA-Na oral administration, the pharmacokinetic parameters, such as plasma valproic acid (VPA) and area under the plasma concentration-time curve up to 3 h (AUC0–3), were significantly decreased compared with those in the control group. However, when rizatriptan benzoate was administered intraperitoneally immediately after VPA-Na orally, these parameters were not changed. In addition, when benzoic acid was administered orally immediately after VPA-Na orally, these were significantly lower compared with the control values. Therefore, it might be possible that VPA transport by monocarboxylate transporter was competitively inhibited by rizatriptan benzoate and thus absorption of VPA was decreased.
- Published
- 2007